

해외 바이오의약품 임상 현황 ('23년 11월 1주)

한국바이오의약품협회, 2023.11.07.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.
URL을 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov
- 모니터링 기간: 2023.10.30.~2023.11.05.
- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 76건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06090864	ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells	Drug: Chemotherapy Biological: Cell infusion	UNC Lineberger Comprehensive Cancer Center	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06090864
NCT06063850	AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy	Genetic: AAV9-hSyn1-miGRIK2	uniQure France SAS UniQure Biopharma B.V.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06063850
NCT06053242	Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain	Drug: CELZ-201-DDT Other: Placebo	Creative Medical Technology Holdings Inc	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06053242
NCT06026657	Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer	Procedure: Biospecimen Collection Procedure: Computed Tomography Drug: Gemcitabine Procedure: Magnetic Resonance Imaging Biological: Naxitamab Biological: Universal Donor Expanded TGF-beta-imprinted NK Cells	Margaret Gatti-Mays Ohio State University Comprehensive Cancer Center	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06026657
NCT05848687	TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II	Drug: Dexamethasone Drug: Mitoxantrone Drug: PEG asparaginase Drug: Bortezomib Drug: Vorinostat Drug: Mercaptopurine Drug: Methotrexate Drug: Blinatumomab Drug: Ziftomenib	Stanford University Pediatric Oncology Experimental Therapeutics Investigators' Consortium Amgen Lucile Packard Foundation for Children's Health	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05848687
NCT05986864	Phase I/II Study of SKG0106 Intraocular Solution in Patients With Neovascular Age-related Macular Degeneration (nAMD)	Genetic: SKG0106	Skyline Therapeutics (US) Inc. Skyline Therapeutics	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05986864
NCT06105931	Physiologic Markers of Cardiometabolic Risk in People With Type 1 Diabetes	Biological: Hyperinsulinemic-euglycemic clamp Other: High Fat Mixed Meal Tolerance Test	Yale University National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06105931
NCT06103877	A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers	Biological: AZD1163 Other: Placebo	AstraZeneca Parexel	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06103877
NCT06100913	Immunology of Ebola Vaccine	Biological: Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSVΔG-ZEBOV-GP)	Emory University Washington University School of Medicine Merck Sharp & Dohme LLC	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06100913
NCT06100705	Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC	Drug: Testosterone Cypionate Drug: Sipuleucel-T	Yale University Dendreon	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06100705
NCT06100237	Teclistamab or Talquetamab in Combination With Daratumumab for High-Risk Smoldering Myeloma (REVIVE Study)	Drug: Teclistamab Drug: Talquetamab Drug: Daratumumab SC	University of Miami Janssen Scientific Affairs, LLC	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06100237
NCT06083454	Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)	Drug: Durvalumab Drug: Pharmacological ascorbate Procedure: Surgery (SOC)	Muhammad Furqan University of Iowa	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06083454

해외 바이오의약품 임상 현황 ('23년 11월 1주)

한국바이오의약품협회, 2023.11.07.

○ 미국 76건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06070012	Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma	Drug: Tebentafusp	Diwakar Davar Immucore Ltd University of Pittsburgh	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06070012
NCT06062966	The Effects of IL-1 Blockade on Inotropic Sensitivity in Patients With Heart Failure (AID-HEART)	Drug: Anakinra	Virginia Commonwealth University	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06062966
NCT06058377	Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer	Procedure: Biospecimen Collection Drug: Cyclophosphamide Drug: Doxorubicin Biological: Durvalumab Other: Genetic Testing Procedure: Mammography Drug: Paclitaxel Other: Quality-of-Life Assessment	National Cancer Institute (NCI)	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06058377
NCT06034470	Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms	Procedure: Biospecimen Collection Procedure: Bone Marrow Aspiration Procedure: Bone Marrow Biopsy Drug: Cytarabine Procedure: Echocardiography Drug: Fludarabine Drug: Granulocyte Colony-Stimulating Factor Drug: Idarubicin Procedure: Multigated Acquisition Scan Drug: Pivekimab Sunirine	Fred Hutchinson Cancer Center ImmunoGen, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06034470
NCT06028932	A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients	Drug: Sacituzumab govitecan	Alessandro Santin Gilead Sciences Yale University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06028932
NCT06027268	Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer	Drug: Trilaciclib Drug: Pembrolizumab Drug: Gemcitabine Drug: Carboplatin	Wake Forest University Health Sciences Merck Sharp & Dohme LLC G1 Therapeutics, Inc.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06027268
NCT06027229	Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations	Biological: NVX-CoV2372	University of Wisconsin, Madison Novavax	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06027229
NCT06018337	A Study of DB-1303 vs Investigator's Choice Chemotherapy in Metastatic Breast Cancer	Drug: DB-1303 Drug: Capecitabine Drug: Paclitaxel Drug: Nab-paclitaxel	DualityBio Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06018337
NCT06017297	Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma	Drug: Durvalumab Drug: Tremelimumab Drug: Gemcitabine Drug: Cisplatin Procedure: Surgical Resection	Georgetown University AstraZeneca	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06017297
NCT06005740	First in Human Study of TORL-4-500 in Participants With Advanced Cancer	Drug: TORL-4-500	TORL Biotherapeutics, LLC Translational Research in Oncology	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06005740
NCT06004336	A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)	Drug: Pembrolizumab Radiation: Radiation therapy	M.D. Anderson Cancer Center Merck Sharp & Dohme LLC Cancer Prevention Research Institute of Texas	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06004336
NCT05987423	A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Thyroid Eye Disease	Drug: Satralizumab Other: Placebo	Hoffmann-La Roche	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05987423
NCT05983133	A Study of SGN-EGFRd2 in Advanced Solid Tumors	Drug: SGN-EGFRd2	Seagen Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05983133
NCT05950334	FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)	Drug: FT522 Drug: Rituximab Drug: Cyclophosphamide Drug: Fludarabine Drug: Bendamustine	Fate Therapeutics	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05950334

해외 바이오의약품 임상 현황 ('23년 11월 1주)

한국바이오의약품협회, 2023.11.07.

○ 미국 76건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05947071	High vs.Standard Dose Influenza Vaccine in Pediatric SOT Recipients	Biological: Standard Dose Quadrivalent Inactivated Influenza Vaccine Biological: High Dose Quadrivalent Inactivated Influenza Vaccine	Vanderbilt University Medical Center Children's Hospital Medical Center, Cincinnati Lucile Packard Children's Hospital University of Pittsburgh Ann & Robert H Lurie Children's Hospital of Chicago Baylor College of Medicine Children's Mercy Hospital Kansas City Children's Healthcare of Atlanta	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05947071
NCT05854966	CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)	Drug: CPI 613 Drug: Metformin Biological: Blood draws Procedure: Bone marrow biopsy	Wake Forest University Health Sciences National Cancer Institute (NCI) Cornerstone Pharmaceuticals	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05854966
NCT05848843	A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations	Drug: Durvalumab Drug: Adagrasib	M.D. Anderson Cancer Center AstraZeneca Mirati Therapeutics Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05848843
NCT05847569	Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma	Biological: Belantamab Mafodotin Procedure: Biospecimen Collection Procedure: Bone Marrow Aspirate Procedure: Bone Marrow Biopsy Procedure: Computed Tomography Procedure: Magnetic Resonance Imaging Procedure: Positron Emission Tomography	Mayo Clinic	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05847569
NCT05829460	Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia	Drug: Semaglutide Drug: Placebo Drug: Progesterin Behavioral: Telemedicine behavioral weight intervention	Washington University School of Medicine Novo Nordisk A/S	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05829460
NCT05805371	PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer	Biological: Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Bone Scan Procedure: Computed Tomography Radiation: External Beam Radiation Therapy Procedure: Leukapheresis Procedure: Lymphodepletion Therapy	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05805371
NCT05802056	Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis	Biological: Aldesleukin Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Procedure: Diagnostic Laparoscopy Drug: Fluorouracil Drug: Leucovorin Calcium Procedure: Magnetic Resonance Imaging Biological: Nivolumab Drug: Oxaliplatin Procedure: Positron Emission Tomography	Mayo Clinic	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05802056
NCT05707702	Lactobacillus Lozenges as Preventative Care in Low-grade Dysplasia	Biological: Probiotic oral lozenges Other: Standard of care for oral dysplasia	Boston Medical Center University of Alabama at Birmingham	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05707702
NCT05672147	CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia	Biological: Anti-CD33 CAR T-cells Procedure: Lymphodepletion Therapy	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05672147

해외 바이오의약품 임상 현황 ('23년 11월 1주)

한국바이오의약품협회, 2023.11.07.

○ 미국 76건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05664113	Feasibility, Safety, and Potential Efficacy of Fecal Microbiota Transplantation (FMT) for Gastrointestinal Dysfunction in Children Following Hematopoietic Cell Transplant (HCT).	Drug: Fecal microbiota transplant (FMT)	St. Jude Children's Research Hospital	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05664113
NCT05618925	Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma	Drug: N803 Biological: CD19t-haNK suspension Drug: Cyclophosphamide Drug: Fludarabine Drug: Rituximab	ImmunityBio, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05618925
NCT05609994	ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas	Drug: PEPIDH1M vaccine + vorasidenib	Katy Peters, MD, PhD Servier Duke University	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05609994
NCT05604560	A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer	Drug: Tislelizumab Drug: SX-682	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins BeiGene Syntrix Biosystems, Inc.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05604560
NCT05424003	Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant	Drug: Semaglutide Pen Injector Drug: Placebo	Virginia Commonwealth University Novo Nordisk A/S	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05424003
NCT05417165	Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia	Biological: Pneumococcal 13-valent Conjugate Vaccine Biological: Pneumococcal Polyvalent Vaccine	Seema Bhat Ohio State University Comprehensive Cancer Center	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05417165
NCT05400603	Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed or Refractory Neuroblastoma	Combination Product: Ex Vivo Expanded Allogeneic $\gamma\delta$ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate	Emory University	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05400603
NCT05067595	Fecal Microbiota Transplant and Dietary Fiber Supplementation for the Treatment of Gut Graft Versus Host Disease	Procedure: Colonoscopy Biological: Fecal Microbiota Transplantation Dietary Supplement: Nutritional Supplementation Other: Survey Administration	Fred Hutchinson Cancer Center	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05067595
NCT04579523	²¹¹ At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma	Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Biological: Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10 Drug: Cyclophosphamide Drug: Fludarabine Phosphate Radiation: Total-Body Irradiation	Fred Hutchinson Cancer Center National Cancer Institute (NCI)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT04579523
NCT04569461	Trimodality Approach of Low Dose iONizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON)	Drug: pembrolizumab Radiation: Stereotactic body radiation therapy Drug: Short-term androgen deprivation therapy Procedure: Radical Prostatectomy	Daniel George, MD Merck Sharp & Dohme LLC Duke University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04569461
NCT04093323	Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma	Biological: Alpha-type-1 Polarized Dendritic Cells Drug: Celecoxib Drug: PD-1 Ligand Inhibitor Drug: PD1 Inhibitor Biological: Recombinant Interferon Alfa-2b Drug: Rintatolimod	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04093323
NCT03988283	Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors	Biological: Personalized neoantigen DNA vaccine Device: Ichor TDS-IM v2.0 Procedure: Peripheral blood draw	Washington University School of Medicine Children's Discovery Institute	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT03988283

해외 바이오의약품 임상 현황 ('23년 11월 1주)

한국바이오의약품협회, 2023.11.07.

○ 미국 76건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06108479	Study of DF6215 in Patients With Advanced Solid Tumors	Drug: DF6215	Dragonfly Therapeutics	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06108479
NCT05231122	Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer	Biological: Anti-CD40 Agonist Monoclonal Antibody CDX-1140 Biological: Bevacizumab Biological: Pembrolizumab Other: Quality-of-Life Assessment Other: Questionnaire Administration	Roswell Park Cancer Institute National Cancer Institute (NCI) Merck Sharp & Dohme LLC Celldex Therapeutics	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05231122
NCT03258658	Safety and Feasibility Study of Autologous Engineered Urethral Constructs for the Treatment of Strictures	Biological: Autologous Engineered Urethral Construct	Wake Forest University Health Sciences United States Department of Defense	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT03258658
NCT05908786	A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma	Drug: Atezolizumab Drug: Bevacizumab Drug: Tiragolumab Drug: Tobemstomig	Hoffmann-La Roche	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05908786
NCT05954871	Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer	Drug: GDC-1971 Drug: Osimertinib Drug: Cetuximab	Genentech, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05954871
NCT05669014	A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)	Drug: Daxdilimab Drug: Placebo	Horizon Therapeutics Ireland DAC Horizon Pharma Ireland, Ltd., Dublin Ireland	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05669014
NCT06104618	Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis	Drug: Enfortumab Vedotin	Mayo Clinic	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06104618
NCT05846789	Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers	Drug: Carboplatin Drug: Tocilizumab	Kathy Miller Genentech, Inc. Indiana University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05846789
NCT05588388	Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases	Drug: Bevacizumab	Kamya Sankar Genentech, Inc. University of Michigan VA Ann Arbor Healthcare System Cedars-Sinai Medical Center	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05588388
NCT05479045	A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients	Biological: NY-ESO-1 Peptide vaccine Drug: Nivolumab	Georgetown University United States Department of Defense Bristol-Myers Squibb	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05479045
NCT05756569	Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology	Procedure: Biospecimen Collection Procedure: Computed Tomography Drug: Enfortumab Vedotin Procedure: Magnetic Resonance Imaging Biological: Pembrolizumab Other: Questionnaire Administration	Emory University National Cancer Institute (NCI) Seagen Inc. Astellas Pharma Inc Merck Sharp & Dohme LLC	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05756569
NCT05937152	A Study of CGRP Monoclonal Antibody to Treat Diabetic Neuropathy	Drug: Eptinezumab Drug: Placebo	Mayo Clinic	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05937152

해외 바이오의약품 임상 현황 ('23년 11월 1주)

한국바이오의약품협회, 2023.11.07.

○ 미국 76건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05874193	A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma	Drug: Belantamab mafodotin	Cristiana Costa Chase, DO Duke University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05874193
NCT05491603	A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis	Biological: DBI-001 Biological: DBI-002 Biological: Aqueous Gel	DermBiont, Inc.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05491603
NCT05985681	Testing RG1-VLP Vaccine to Prevent HPV-related Cancers	Procedure: Biospecimen Collection Biological: HPV16 RG1 VLP Vaccine Other: Questionnaire Administration Biological: Recombinant Human Papillomavirus Nonavalent Vaccine Other: Saline	National Cancer Institute (NCI)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05985681
NCT06001385	HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis	Drug: Busulfan Drug: Fludarabine Procedure: PBSC Hematopoietic Stem Cell Transplantation (HSCT) Drug: Post-Transplant Cyclophosphamide Drug: Mesna Drug: Tacrolimus Drug: Mycophenolate Mofetil Other: Patient Reported Outcomes Drug: Melphalan Radiation: Total-body irradiation Drug: Cyclophosphamide	Center for International Blood and Marrow Transplant Research National Marrow Donor Program	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06001385
NCT06071767	Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1	Biological: ChAdOx1.tHIVconsv1 Biological: ChAdOx1.HIVconsv2 Biological: MVA.tHIVconsv3 Biological: MVA.tHIVconsv4 Drug: Vesatolimod (VES) Drug: GS-5423 Drug: GS-2872 Biological: Placebo	National Institute of Allergy and Infectious Diseases (NIAID) University of Oxford Gilead Sciences	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06071767
NCT05987332	IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma	Drug: IDE196 Drug: Crizotinib Drug: Pembrolizumab Drug: Ipilimumab Drug: Nivolumab Drug: Dacarbazine	IDEAYA Biosciences	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05987332
NCT06110793	A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer	Drug: Lenvatinib Drug: Pembrolizumab Drug: Fulvestrant	Memorial Sloan Kettering Cancer Center Merck Sharp & Dohme LLC	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06110793
NCT05642455	SPEARHEAD-3 Pediatric Study	Genetic: Afamitresgene autoleucel	Adaptimmune	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05642455
NCT06116916	A Phase 2 Study to Assess the Efficacy and Safety of KHK4951 in Patients With Diabetic Macular Edema	Drug: KHK4951 Drug: Aflibercept Injection	Kyowa Kirin, Inc.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06116916
NCT06116890	A Phase 2 Study to Assess the Efficacy and Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration	Drug: KHK4951 Drug: Aflibercept Injection	Kyowa Kirin, Inc.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06116890
NCT06055608	Advancing Transplantation Outcomes in Children	Drug: Sirolimus Biological: Belatacept Drug: Mycophenolate Mofetil Drug: Tacrolimus (Group 1) Drug: Anti-Thymocyte Globulin (ATG) Drug: Tacrolimus (Group 2)	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06055608
NCT06006546	The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies	Biological: 426c.Mod.Core-C4b Other: Adjuvant 3M-052-AF+Alum	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06006546
NCT05997264	Anthrax AV7909 Boost Evaluation Study	Biological: AV7909 Full Dose (0.5 mL) Biological: AV7909 Half Dose (0.25 mL)	Biomedical Advanced Research and Development Authority Rho Federal Systems Division, Inc. ICON plc	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05997264

해외 바이오의약품 임상 현황 ('23년 11월 1주)

한국바이오의약품협회, 2023.11.07.

○ 미국 76건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05063565	TheraSphere With Durvalumab and Tremelimumab for HCC	Device: TheraSphere Y-90 glass microsphere therapy Drug: Durvalumab (Imfinzi) immunotherapy Drug: Tremelimumab immunotherapy	Boston Scientific Corporation Biocompatibles UK Ltd	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05063565
NCT05733598	RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC	Biological: RP3 Biological: atezolizumab Biological: bevacizumab	Replimune Inc. Roche Pharma AG	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05733598
NCT03929601	Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes	Drug: Rituximab-pvvr Drug: Abatacept Drug: Sterile Sodium Chloride	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) National Institutes of Health (NIH)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT03929601
NCT06094296	A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)	Drug: BMS-986315 Drug: Nivolumab Drug: Pemetrexed Drug: Cisplatin Drug: Carboplatin Drug: Paclitaxel	Bristol-Myers Squibb	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06094296

○ 영국 5건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05208242	Strong Albumin Solutions in Patients With Septic Shock	Drug: hyperoncotic human albumin solution Drug: Buffered crystalloid solutions	Manchester University NHS Foundation Trust University of Manchester	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05208242
NCT06045910	A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies	Drug: ALETA-001	Cancer Research UK Aleta BioTherapeutics	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06045910
NCT05770102	DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition	Drug: Atezolizumab	Cancer Research UK University of Manchester University of Birmingham Royal Marsden NHS Foundation Trust Hoffmann-La Roche	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05770102
NCT05733598	RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC	Biological: RP3 Biological: atezolizumab Biological: bevacizumab	Replimune Inc. Roche Pharma AG	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05733598
NCT05987332	IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma	Drug: IDE196 Drug: Crizotinib Drug: Pembrolizumab Drug: Ipilimumab Drug: Nivolumab Drug: Dacarbazine	IDEAYA Biosciences	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05987332

○ 프랑스 3건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05800275	Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease	Drug: Tucatinib Oral Tablet Drug: Capecitabine tablets Drug: Trastuzumab Injection	UNICANCER Seagen Inc.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05800275
NCT05733598	RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC	Biological: RP3 Biological: atezolizumab Biological: bevacizumab	Replimune Inc. Roche Pharma AG	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05733598
NCT05987332	IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma	Drug: IDE196 Drug: Crizotinib Drug: Pembrolizumab Drug: Ipilimumab Drug: Nivolumab Drug: Dacarbazine	IDEAYA Biosciences	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05987332

해외 바이오의약품 임상 현황 ('23년 11월 1주)

한국바이오의약품협회, 2023.11.07.

○ 독일 3건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05987332	IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma	Drug: IDE196 Drug: Crizotinib Drug: Pembrolizumab Drug: Ipilimumab Drug: Nivolumab Drug: Dacarbazine	IDEAYA Biosciences	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05987332
NCT05733598	RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC	Biological: RP3 Biological: atezolizumab Biological: bevacizumab	Replimune Inc. Roche Pharma AG	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05733598
NCT06091020	A Clinical Trial to Investigate Efficacy and Safety of NT 201 Injections Compared With Placebo Injections in Participants Aged 18 Years and Older With Chronic Nerve Pain After Shingles or Nerve Injury	Biological: IncobotulinumtoxinA Biological: Placebo	Merz Therapeutics GmbH Merz Pharmaceuticals GmbH	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06091020

○ 중국 31건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06111638	Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs	Genetic: Single dose intravenous injection of BBM-H803	Shanghai Belief-Delivery BioMed Co., Ltd Shanghai MYGT Biopharmaceutical LLC	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06111638
NCT06066203	A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies	Drug: GNC-035	Sichuan Baili Pharmaceutical Co., Ltd.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06066203
NCT06031584	A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors	Drug: BL-M07D1	Sichuan Baili Pharmaceutical Co., Ltd.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06031584
NCT05832892	Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer	Drug: surufatinib Drug: KN046 Drug: gemcitabine Drug: Nab paclitaxel	Shanghai Zhongshan Hospital Fudan University	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05832892
NCT06110338	Safety and Tolerance Study of IBI355 in Health Volunteers	Drug: placebo Drug: IBI355	Innovent Biologics (Suzhou) Co. Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06110338
NCT06109402	Perioperative Immunotherapy Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer	Drug: TQB2450 Drug: Carboplatin Drug: Pemetrexed Drug: Nab-paclitaxel Procedure: Surgery	Shanghai Pulmonary Hospital, Shanghai, China	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06109402
NCT06109207	Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Esophageal or Head and Neck Squamous Cell Carcinomas	Drug: Camrelizumab Drug: Dalpiciclib 100mg Drug: Dalpiciclib 150mg	West China Hospital	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06109207
NCT06107686	A Study of YL202 in Selected Patients With Advanced Solid Tumors	Drug: YL202 should be intravenously infused	MediLink Therapeutics (Suzhou) Co., Ltd.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06107686
NCT06107114	Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell Carcinoma	Drug: Cetuximab Drug: Zimberelimab Drug: Docetaxel Drug: Cisplatin	Xuekui Liu Sun Yat-sen University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06107114
NCT06094881	A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)	Drug: Obinutuzumab Injection [Gazyva]	Institute of Hematology & Blood Diseases Hospital, China	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06094881

해외 바이오의약품 임상 현황 ('23년 11월 1주)

한국바이오의약품협회, 2023.11.07.

○ 중국 31건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06092645	Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma	Drug: surufatinib plus cadonilimab	Zhejiang Cancer Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06092645
NCT06090799	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3032 in Healthy Subjects	Drug: SHR-3032 Drug: SHR-3032 Placebo	Guangdong Hengrui Pharmaceutical Co., Ltd	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06090799
NCT06089382	A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection	Drug: Sintilimab Drug: Lenvatinib Procedure: Transarterial Chemoembolization (TACE)	Tongji Hospital	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06089382
NCT06089369	Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion	Biological: Sintilimab Procedure: Transarterial Chemoembolization (TACE)	Tongji Hospital	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06089369
NCT06088459	NWRD06 DNA Plasmid for HCC After Radical Resection	Biological: 1mg NWRD06 administered by electroporation Biological: 4mg NWRD06 administered by electroporation Biological: 8mg NWRD06 administered by electroporation	Newish Technology (Beijing) Co., Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06088459
NCT06084286	Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients With CLDN18.2-positive Advanced Solid Tumors	Biological: Dual-targeting CLDN18.2 and PD-L1 CAR-T cells	Sichuan University	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06084286
NCT06081907	The Efficacy and Safety of IBI363 in Solid Tumors.	Drug: IBI363	Hunan Province Tumor Hospital Xiangya Hospital of Central South University	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06081907
NCT06081673	Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC	Drug: Penpulimab injection Drug: cisplatin Drug: albumin-paclitaxel	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06081673
NCT06080256	Extra Alirocumab in Addition to Statin Therapy in Asymptomatic Intracranial Atherosclerotic Stenosis (EAST-aICAS)	Drug: Alirocumab Drug: Atorvastatin	The First Affiliated Hospital with Nanjing Medical University	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06080256
NCT06070740	First-Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma	Drug: Durvalumab and Chemotherapy(oxaliplatin and capecitabine)	Peking Union Medical College Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06070740
NCT06060704	Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.	Drug: Envafolimab Drug: Trifluridine/Tipiracil Drug: Bevacizumab	The First Affiliated Hospital with Nanjing Medical University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06060704
NCT06056050	A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above)	Biological: Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Aged 6 Years and Older) (Tdcp) Biological: 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) Biological: Diphtheria and Tetanus Combined Vaccine, Adsorbed (DT)	CanSino Biologics Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06056050

해외 바이오의약품 임상 현황 ('23년 11월 1주)

한국바이오의약품협회, 2023.11.07.

○ 중국 31건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06042894	A Study of BL-B01D1 + SI-B003 in Patients With Unresectable, Locally Advanced or Recurrent Metastatic HER2-negative Breast Cancer	Drug: BL-B01D1 Drug: SI-B003	Sichuan Baili Pharmaceutical Co., Ltd.	Phase 2	http://ctdlib.nih.gov/study/NCT06042894
NCT06031480	Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors	Drug: Anlotinib and TQB2450	Shanghai Zhongshan Hospital Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 2	http://ctdlib.nih.gov/study/NCT06031480
NCT06006741	Universal CAR-T Cells Targeting Multiple Myeloma	Biological: MM-specific universal CAR T cells	Shenzhen Geno-Immune Medical Institute	Phase 1	http://ctdlib.nih.gov/study/NCT06006741
NCT05995041	Universal CAR-T Cells Targeting AML	Biological: CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells	Shenzhen Geno-Immune Medical Institute	Phase 1	http://ctdlib.nih.gov/study/NCT05995041
NCT05995028	Universal 4SCAR7U Targeting CD7-positive Malignancies	Biological: Universal CD7-specific CAR gene-engineered T cells	Shenzhen Geno-Immune Medical Institute	Phase 1	http://ctdlib.nih.gov/study/NCT05995028
NCT05995015	4SCAR19U T Cells Targeting B Cell Malignancies	Biological: Universal CD19-specific CAR gene-engineered T cells	Shenzhen Geno-Immune Medical Institute	Phase 1	http://ctdlib.nih.gov/study/NCT05995015
NCT06030258	IN10018 Combination Therapy in Treatment-naïve ES-SCLC	Drug: IN10018 Drug: Tislelizumab Drug: Carboplatin Drug: Etoposide	InxMed (Shanghai) Co., Ltd.	Phase 1 Phase 2	http://ctdlib.nih.gov/study/NCT06030258
NCT06115902	A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer	Drug: TQB2102 for injection	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 1	http://ctdlib.nih.gov/study/NCT06115902
NCT06093841	Relmacabtagene Autoleucl as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL	Biological: Relmacabtagene Autoleucl Drug: Fludarabine Drug: Cyclophosphamide	Shanghai Ming Ju Biotechnology Co., Ltd.	Phase 2	http://ctdlib.nih.gov/study/NCT06093841

○ 일본 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06116916	A Phase 2 Study to Assess the Efficacy and Safety of KHK4951 in Patients With Diabetic Macular Edema	Drug: KHK4951 Drug: Aflibercept Injection	Kyowa Kirin, Inc.	Phase 2	http://ctdlib.nih.gov/study/NCT06116916
NCT06116890	A Phase 2 Study to Assess the Efficacy and Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration	Drug: KHK4951 Drug: Aflibercept Injection	Kyowa Kirin, Inc.	Phase 2	http://ctdlib.nih.gov/study/NCT06116890